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small, reflect the early stages and the patho-
genesis of fatal human cases.
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Use of autologous adult stem cell for
treatment of congestive heart failure
To the Editor:
I read the article by Patel entitled “Surgical
treatment for congestive heart failure with
autologous adult stem cell transplantation: A
prospective randomized study” with great in-
terest.1-4 Clearly the authors have demon-
strated the effectiveness of injected autolo-
gous bone marrow stem cells to improve the
functional capacity of the failing heart.3-5 In
this clinical study they had the opportunity
to take biopsy specimens of myocardium at
the injection sites, but the nature of the cell
findings are not reported.
Did the biopsy specimens show the
CD34 marker?
Because no information is available in
regard to the presence of fibroblasts or scar
tissue, would it be possible that these tis-
sues are transforming through dedifferenti-
ation into myocardial tissue instead of stem
cell transformation? The implication of this
concept will allow investigators to concen-
trate more on the transduction signal path-
way rather than stem cells alone.
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Positron emission tomographic
scanning in the diagnosis and
staging of non–small cell lung
cancer 2 cm in size or less
To the Editor:
We read with interest the publication by
Port and colleagues.1 In fact, there is little
information in the literature on the role of
positron emission tomography (PET) in as-
sessing lung lesions of this size range for
malignancy, and well-defined studies are
needed. However, the current publication
has several shortcomings.
Most importantly, standard uptake value
(SUV) should not have been used to assess
the lung lesions for malignancy. SUV is a
semiquantitative measure of the tracer up-
take in the region of interest, which nor-
malizes the lesion activity to the injected
dose and body weight; SUV does not have
a unit. Despite initial enthusiasm, it is gen-
erally accepted that SUV should not be
used to differentiate malignant from benign
processes and that the visual interpretation
of PET studies by an experienced reader
provides the highest accuracy in diagnos-
ing malignancy.2-5 There are many factors
influencing the calculation of SUV, such as
the body weight and composition, the time
between tracer injection and image acqui-
sition, the spatial resolution of the PET
scanner, and the image reconstruction algo-
rithm. The clinical role of SUV in therapy
monitoring and as a measure of tumor ag-
gressiveness is currently under investigation.
Furthermore, the intensity of malignant
lesions on PET is influenced by the loca-
tion in the body. During PET acquisition,
which takes several minutes, lung lesions
move up and down, and their effective ac-
quisition time is reduced. Therefore the
fluorodeoxyglucose avidity of small lung
lesions is often underestimated. Conse-
quently, it is justified to use a “sensitive
reading” and consider tumors of mild in-
tensity to be malignant, although this likely
reduces the specificity. Additionally, the
non–attenuation-corrected (NAC) images
should be reviewed while dealing with
small lung lesions. Considering the mildly
intense appearance of small malignant lung
lesions on PET, it is reasonable to use the
NAC images and compare the tumor up-
take with the surrounding normal lung tis-
sue and not with the mediastinal blood pool
activity, as is the case while reading the
attenuation-corrected (AC) images. Although
large and markedly intense malignant foci
would likely be recognized on both NAC
and AC images, this might not be the case
for small foci. Also, the pathophysiologic
basis of fluorodeoxyglucose PET rests on
increased expression of Glut, upregulation
of hexokinase activity, and downregulation
of glucose-6-phosphatase activity in the
cancer cells compared with the normal cells
of the same organ, the lung in this case.
In our experience PET can be very help-
ful in detecting malignancy in lung lesions
measuring 6 to 10 mm, provided the im-
ages are read with attention to the issues
mentioned (NAC images, sensitive read-
ing, and avoidance of SUV thresholds).
Sensitivity and specificity of PET for de-
tecting malignancy in small lung lesions
(6-10 mm) is currently being evaluated by
us in an ongoing prospective study.
Amir H. Khandani, MD, PhDa
Frank C. Detterbeck, MDb
Department of Radiologya
UNC School of Medicine
CB #7510, Chapel Hill, NC 27599-7510
E-mail: khandani@med.unc.edu
Department of Surgeryb
Yale University School of Medicine
New Haven, Conn
Letters to the Editor
214 The Journal of Thoracic and Cardiovascular Surgery ● July 2006
